Teachers Retirement System of The State of Kentucky Purchases Shares of 110,000 Elanco Animal Health Incorporated $ELAN

Teachers Retirement System of The State of Kentucky purchased a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 110,000 shares of the company’s stock, valued at approximately $2,215,000.

Several other hedge funds have also recently modified their holdings of the stock. AlphaQuest LLC grew its position in Elanco Animal Health by 13.7% during the 3rd quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after purchasing an additional 718 shares during the last quarter. Jones Financial Companies Lllp raised its stake in Elanco Animal Health by 15.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock worth $119,000 after acquiring an additional 798 shares during the last quarter. MTM Investment Management LLC grew its stake in Elanco Animal Health by 5.5% during the 2nd quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock valued at $218,000 after purchasing an additional 800 shares during the last quarter. US Bancorp DE increased its holdings in shares of Elanco Animal Health by 1.9% in the third quarter. US Bancorp DE now owns 43,810 shares of the company’s stock valued at $882,000 after purchasing an additional 824 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. KeyCorp upped their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. Finally, Leerink Partners lifted their price target on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and a consensus price target of $27.67.

Elanco Animal Health Stock Down 2.0%

Shares of Elanco Animal Health stock opened at $23.95 on Friday. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $27.72. The company has a 50 day moving average of $24.43 and a 200 day moving average of $21.95. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $11.91 billion, a P/E ratio of -49.89, a P/E/G ratio of 3.11 and a beta of 1.83.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Activity at Elanco Animal Health

In related news, insider Rajeev A. Modi purchased 4,500 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the purchase, the insider directly owned 123,082 shares of the company’s stock, valued at $2,625,339.06. The trade was a 3.79% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons bought 22,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were acquired at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the transaction, the chief executive officer owned 167,000 shares of the company’s stock, valued at approximately $3,632,250. The trade was a 15.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 43,450 shares of company stock valued at $937,883. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.